Filing Details

Accession Number:
0001104659-16-126661
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-10 21:40:32
Reporting Period:
2016-06-08
Filing Date:
2016-06-10
Accepted Time:
2016-06-10 21:40:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1419600 Flexion Therapeutics Inc FLXN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1279592 N Barbara Lubash One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1354345 Phd J Bradley Bolzon One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1354802 M Charles Warden One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1456588 L. Robin Praeger One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-06-08 710,091 $14.00 3,511,670 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-06-08 4,194 $14.00 20,739 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 388,683 Indirect See Footnote
Footnotes
  1. The shares are held by Versant Venture Capital III, L.P. ("VVC III"). Versant Ventures III, LLC, a Delaware limited liability company ("VV III") serves as the sole general partner of VVC III. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and dispositive power over the shares held by VVC III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.
  2. The shares are held by Versant Side Fund III, L.P. ("VSF III"). VV III serves as the sole general partner of VSF III. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and dispositive power over the shares held by VSF III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.
  3. The shares are held by Versant Development Fund III, LLC ("Development III"). Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and investment authority over the shares held by Development III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.